首页> 中文期刊> 《基层医学论坛》 >血清CA125和骨桥蛋白联合检测对卵巢癌的诊断价值

血清CA125和骨桥蛋白联合检测对卵巢癌的诊断价值

             

摘要

Objective To study the value of the diagnose ovary cancer by joint detecting CA125 and OPN. Methods OPN was determined using ELISA method and CA125 level was detected by ELISA in ovary cancer group、Benign ovarian tumor group and Normal control group ,then compare and analyze each index of serum concentration and positive rate. Results The level of CA125 and OPN in the ovary cancer group was higher than the Benign ovarian tumor group and the Normal control group. The level of CA125 and OPN in the Benign ovarian tumor were higher than the Normal control group .Single positive rate and joint positive rate of CA125 and OPN in the ovary cancer group were higher than the Benign ovarian tumor group and the Normal control group .And the joint positive rate of CA125 and OPN were higher than the single positive rate .There was remarkable difference among the groups. Joint detection in the early ovarian cancer is better than that of advanced ovarian cancer. Conclusion The joint detection of ovarian cancer patients with CA125 and OPN is better than the single detection. It contributes to early diagnosis and improves the accuracy of diagnosis of ovarian cancer.%目的:探讨联合检测血清CA125和骨桥蛋白(OPN)对卵巢癌的诊断价值。方法分别采用化学发光法及ELISA法检测卵巢癌、卵巢良性肿瘤、正常对照组的CA125和OPN水平,对其血清浓度以及阳性率进行统计分析。结果卵巢癌组的CA125和OPN水平明显高于良性肿瘤组及正常对照组,差异有显著性(P<0.05);良性肿瘤组CA125和OPN明显高于正常对照组,差异有显著性(P<0.05);卵巢癌组的CA125、OPN单项检测及联合检测的阳性率均明显高于良性肿瘤组及正常对照组,差异有显著性(P<0.05);卵巢癌组CA125和OPN联合检测的阳性率明显高于单项检测的阳性率(P<0.05),且联合检测在早期卵巢癌优于晚期卵巢癌。结论联合检测卵巢癌患者血清CA125和OPN优于单项检测,且联合检测可明显提高卵巢癌的早期诊断率,以及卵巢癌的诊断准确率。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号